Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission leads to the
emergence of variants, including the B. 1.617. 2 (Delta) variant of concern that is causing a …
emergence of variants, including the B. 1.617. 2 (Delta) variant of concern that is causing a …
[PDF][PDF] Antibody evasion of SARS-CoV-2 Omicron BA. 1, BA. 1.1, BA. 2, and BA. 3 sub-lineages
Summary The SARS-CoV-2 Omicron variant has evolved into four sub-lineages—BA. 1, BA.
1.1, BA. 2, and BA. 3—with BA. 2 becoming dominant worldwide. We and others have …
1.1, BA. 2, and BA. 3—with BA. 2 becoming dominant worldwide. We and others have …
[PDF][PDF] Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
[PDF][PDF] LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - Cell reports, 2022 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
[HTML][HTML] Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Q Zhang, R Xiang, S Huo, Y Zhou, S Jiang… - Signal transduction and …, 2021 - nature.com
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …
Omicron BA. 2 (B. 1.1. 529.2): high potential for becoming the next dominant variant
The Omicron variant has three subvariants: BA. 1 (B. 1.1. 529.1), BA. 2 (B. 1.1. 529.2), and
BA. 3 (B. 1.1. 529.3). BA. 2 is found to be able to alarmingly reinfect patients originally …
BA. 3 (B. 1.1. 529.3). BA. 2 is found to be able to alarmingly reinfect patients originally …
[HTML][HTML] The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
[HTML][HTML] In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
L Wang, T Zhou, Y Zhang, ES Yang, CA Schramm… - Science, 2021 - science.org
INTRODUCTION Worldwide appearance of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B. 1.1. 529
The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …